Accessibility Menu
Labcorp Holdings Inc. logo

Labcorp Holdings Inc.(NYSE) LH

Market Cap$25.21BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1988)+1,719%
5 Year+25%
1 Year+19%
1 Month+7%
$307.29
-0.62%
-1.91Today
Labcorp Holdings Inc. last closing stock price
MetricPriceDate
Last closeUSD 307.422026-08-03
Labcorp Holdings Inc. stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.08%USD 301.172026-07-27
1 month+7.12%USD 286.982026-07-02
3 month+19.88%USD 256.442026-05-05
Year to date+23.18%USD 249.572025-12-31
1 year+18.8%USD 258.772025-08-01
3 year+48.09%USD 207.592023-08-04
5 year+25.49%USD 244.972021-08-04
Since inception+1,718.9%USD 16.901988-07-07

Labcorp Holdings Inc. Financials at a Glance

Market Cap

$25.21BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$14.35B

Net Income (TTM)

$1.00B

EPS (TTM)

$12.09

P/E Ratio

25.43

Dividend

$2.88

Beta (Volatility)

0.61 (Low)

Price

$307.29

Volume

5

Open

$310.03

Previous Close

$307.42

Daily Range

$307.04 - $312.99

52-Week Range

$244.52 - $316.11

Estimated Earnings Date

Oct 27, 2026

LH News

Foolcom-Featured.png

Labcorp Posts 9.5 Percent Gain in Q2

Motley Fool Markets TeamJul 24, 2025
scientists lab testing vaccine development

Why Shares of Labcorp Dropped Monday

James HalleyJul 3, 2023
Person in a lab looking through a microscope

Why Labcorp Stock Sank by Almost 6% on Thursday

Eric VolkmanOct 27, 2022
Woman scientist looking through microscope

Here's How Labcorp Trounced Wall Street Estimates in Q4

Keith SpeightsFeb 11, 2021
pharmacists filling pills

How LabCorp Beat Wall Street's Q2 Estimates

Keith SpeightsJul 28, 2020
clinical-trial-theme-getty

LabCorp Launches New Coronavirus Antibody Test

Cory RenauerJun 25, 2020
GettyImages-1212440479

Why Is Everyone Talking About LabCorp Stock?

Jim CrumlyMay 17, 2020
GettyImages-1221364691

LabCorp Launches COVID-19 Testing Service to Help Workers Get Back on the Job

Jim CrumlyMay 14, 2020
Page 1

LH: Motley Fool Moneyball Superscore

71

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Labcorp Holdings Inc.

Labcorp helps doctors and researchers understand health through medical tests and science. The company turns samples into data to guide treatment and drug development. These services assist hospitals, drug companies, and patients in making medical choices.

What Labcorp Does

  • Diagnostics Laboratories: Testing services including routine blood work, oncology, and genetic testing; generated 78% of revenue in 2025.
  • Biopharma Laboratory Services: Research support for drug development and clinical trials across 100 countries; accounts for 22% of revenue.
  • Early Development Research: Specialized testing for new drug lead optimization and safety assessment before human trials begin.
  • Specialty Testing: Advanced diagnostics for complex diseases like Alzheimer disease, autoimmune disorders, and cancer.

Strategic Moves and Partnerships

  • Acquired a minority stake in SYNLAB during 2025 to expand diagnostic services and specialty testing across Europe.
  • Invested $582 million in strategic business acquisitions during 2025 to enhance service offerings and geographic presence.
  • Launched nationwide self-collection options for human papillomavirus and sexually transmitted infection testing in 2025.
  • Completed 13 collaboration transactions with health systems and local laboratories during 2025 to expand its partnership network.
  • Expanded the cell and gene therapy laboratory in Madison, Wisconsin, to support drug development pipelines.

A Leader in Science and Scale

Labcorp supports roughly 85% of new drugs approved by the FDA in 2025 through its global clinical trial network. The company maintains a massive logistics system that performed more than 750 million tests for patients during the year.

The Recent Financial Record

  • Total revenue reached $13.95 billion for the fiscal year ended Dec. 31, 2025.
  • Operating income rose to $382 million in Q4 2025, up 76.4% from Q4 2024.
  • Net income for Q4 2025 was $164.7 million, up 14.9% year-over-year.
  • Quarterly revenue for Q4 2025 hit $3.5 billion, up 5.6% from the previous year.
  • Free cash flow was $490.3 million in Q4 2025, down 26.3% from Q4 2024.

Bottom Line

Labcorp has transitioned from a domestic laboratory provider to a global life sciences partner integrated into the drug development lifecycle. Its expansion into specialty testing and health system partnerships serves as the foundation for its current business model.

AI Generated • Apr 19, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

Employees

71,000

CEO

Adam H. Schechter

Website

www.labcorp.com

Headquarters

Burlington, NC 27215, US

LH Financials

Key Financial Metrics (TTM)

Gross Margin

27.85%

Operating Margin

11.27%

Net Income Margin

6.99%

Return on Equity

11.57%

Return on Capital

9.58%

Return on Assets

5.41%

Earnings Yield

3.93%

Dividend Yield

0.94%

Payout Ratio

23.86%

Stock Overview

Market Cap

$25.21BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

82.00M

Volume

5

Avg. Volume

697.84K

Financials (TTM)

Gross Profit

$4.00B

Operating Income

$1.62B

EBITDA

$2.15B

Operating Cash Flow

$1.64B

Capital Expenditure

-$483.20M

Free Cash Flow

$1.16B

Cash & ST Invst.

$141.80M

Total Debt

$6.77B

Labcorp Holdings Inc. Performance Analysis

Labcorp Holdings Inc. annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 11,863,900,000-26.4%
20232023-12-31USD 12,161,600,0002.5%
20242024-12-31USD 13,008,900,0007.0%
20252025-12-31USD 13,951,700,0007.2%
Labcorp Holdings Inc. sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-301.0%
Q42025-12-31-1.3%
Q12026-03-310.6%
Q22026-06-305.5%
Labcorp Holdings Inc. annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 13.96-42.7%
20232023-12-31USD 4.77-65.8%
20242024-12-31USD 8.8485.2%
20252025-12-31USD 10.4618.3%
Labcorp Holdings Inc. sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-309.9%
Q42025-12-31-36.5%
Q12026-03-3169.2%
Q22026-06-308.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$3.73B

+5.8%

Gross Profit

$1.11B

+6.3%

Gross Margin

29.80%

N/A

Market Cap

$25.21BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$355.05K

N/A

Employees

71,000

N/A

Net Income

$298.70M

+25.6%

EBITDA

$620.90M

+16.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$141.80M

-78.1%

Total Debt

$6.77B

+3.4%

Accounts Receivable

$2.50B

+10.0%

Inventory

$562.20M

+10.6%

Long Term Debt

$6.58B

+12.4%

Short Term Debt

$185.90M

-73.1%

Return on Assets

5.41%

N/A

Return on Invested Capital

9.86%

N/A

Free Cash Flow

$313.90M

-42.2%

Operating Cash Flow

$445.50M

-28.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
DGXQuest Diagnostics Incorporated
$231.95-0.45%
WSTWest Pharmaceutical Services, Inc.
$348.10+2.09%
WATWaters Corporation
$374.74-0.68%
INCYIncyte Corporation
$118.43-0.91%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.36+0.02%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$23.99+0.01%
PLTRPalantir Technologies
$125.65+0.02%
TQQQProShares Trust - ProShares UltraPro Qqq
$67.96+0.05%

Questions About LH

What is the current price of Labcorp Holdings Inc.?

Labcorp Holdings Inc. is trading at $307.42 per share.

What is the 52-week range for Labcorp Holdings Inc.?

Over the past 52 weeks, Labcorp Holdings Inc. has traded between $244.52 and $316.11.

How much debt does Labcorp Holdings Inc. have?

As of the most recent reporting period, Labcorp Holdings Inc. reported total debt of $6.77B.

How much cash does Labcorp Holdings Inc. have on hand?

Labcorp Holdings Inc. reported $141.80M in cash and cash equivalents in its most recent financial results.

What is Labcorp Holdings Inc.’s dividend yield?

Labcorp Holdings Inc. currently has a dividend yield of 0.94%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services